Literature DB >> 17233820

Fusion of NUP98 and the SET binding protein 1 (SETBP1) gene in a paediatric acute T cell lymphoblastic leukaemia with t(11;18)(p15;q12).

Ioannis Panagopoulos1, Gitte Kerndrup, Niels Carlsen, Bodil Strömbeck, Margareth Isaksson, Bertil Johansson.   

Abstract

Three NUP98 chimaeras have previously been reported in T cell acute lymphoblastic leukaemia (T-ALL): NUP98/ADD3, NUP98/CCDC28A, and NUP98/RAP1GDS1. We report a T-ALL with t(11;18)(p15;q12) resulting in a novel NUP98 fusion. Fluorescent in situ hybridisation showed NUP98 and SET binding protein 1(SETBP1) fusion signals; other analyses showed that exon 12 of NUP98 was fused in-frame with exon 5 of SETBP1. Nested polymerase chain reaction did not amplify the reciprocal SETBP1/NUP98, suggesting that NUP98/SETBP1 transcript is pathogenetically important. SETBP1 has previously not been implicated in leukaemias; however, it encodes a protein that specifically interacts with SET, fused to NUP214 in a case of acute undifferentiated leukaemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17233820     DOI: 10.1111/j.1365-2141.2006.06410.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  24 in total

1.  Amino-terminal enhancer of split (AES) interacts with the oncoprotein NUP98-HOXA9 and enhances its transforming ability.

Authors:  Nayan J Sarma; Nabeel R Yaseen
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  De novo mutations of SETBP1 cause Schinzel-Giedion syndrome.

Authors:  Alexander Hoischen; Bregje W M van Bon; Christian Gilissen; Peer Arts; Bart van Lier; Marloes Steehouwer; Petra de Vries; Rick de Reuver; Nienke Wieskamp; Geert Mortier; Koen Devriendt; Marta Z Amorim; Nicole Revencu; Alexa Kidd; Mafalda Barbosa; Anne Turner; Janine Smith; Christina Oley; Alex Henderson; Ian M Hayes; Elizabeth M Thompson; Han G Brunner; Bert B A de Vries; Joris A Veltman
Journal:  Nat Genet       Date:  2010-05-02       Impact factor: 38.330

Review 3.  Somatic SETBP1 mutations in myeloid neoplasms.

Authors:  Hideki Makishima
Journal:  Int J Hematol       Date:  2017-04-26       Impact factor: 2.490

Review 4.  Protein phosphatase 2A: a target for anticancer therapy.

Authors:  Danilo Perrotti; Paolo Neviani
Journal:  Lancet Oncol       Date:  2013-05       Impact factor: 41.316

Review 5.  NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights.

Authors:  Sheryl M Gough; Christopher I Slape; Peter D Aplan
Journal:  Blood       Date:  2011-09-26       Impact factor: 22.113

6.  Functional analysis of the NUP98-CCDC28A fusion protein.

Authors:  Arnaud Petit; Christine Ragu; Gwendoline Soler; Chris Ottolenghi; Caroline Schluth; Isabelle Radford-Weiss; Sylvie Schneider-Maunoury; Isabelle Callebaut; Nicole Dastugue; Harry A Drabkin; Olivier A Bernard; Serge Romana; Virginie Penard-Lacronique
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

7.  Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.

Authors:  Anupriya Agarwal; Ryan J MacKenzie; Raffaella Pippa; Christopher A Eide; Jessica Oddo; Jeffrey W Tyner; Rosalie Sears; Michael P Vitek; María D Odero; Dale J Christensen; Brian J Druker
Journal:  Clin Cancer Res       Date:  2014-01-16       Impact factor: 12.531

8.  Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.

Authors:  Rocco Piazza; Simona Valletta; Nils Winkelmann; Sara Redaelli; Roberta Spinelli; Alessandra Pirola; Laura Antolini; Luca Mologni; Carla Donadoni; Elli Papaemmanuil; Susanne Schnittger; Dong-Wook Kim; Jacqueline Boultwood; Fabio Rossi; Giuseppe Gaipa; Greta P De Martini; Paola Francia di Celle; Hyun Gyung Jang; Valeria Fantin; Graham R Bignell; Vera Magistroni; Torsten Haferlach; Enrico Maria Pogliani; Peter J Campbell; Andrew J Chase; William J Tapper; Nicholas C P Cross; Carlo Gambacorti-Passerini
Journal:  Nat Genet       Date:  2012-12-09       Impact factor: 38.330

9.  Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines.

Authors:  Stefan Nagel; Letizia Venturini; Victor E Marquez; Corinna Meyer; Maren Kaufmann; Michaela Scherr; Roderick Af MacLeod; Hans G Drexler
Journal:  Mol Cancer       Date:  2010-06-17       Impact factor: 27.401

10.  Second generation sequencing of the mesothelioma tumor genome.

Authors:  Raphael Bueno; Assunta De Rienzo; Lingsheng Dong; Gavin J Gordon; Colin F Hercus; William G Richards; Roderick V Jensen; Arif Anwar; Gautam Maulik; Lucian R Chirieac; Kim-Fong Ho; Bruce E Taillon; Cynthia L Turcotte; Robert G Hercus; Steven R Gullans; David J Sugarbaker
Journal:  PLoS One       Date:  2010-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.